Long-term treatment of bronchial asthma with pirbuterol aerosol.
In an open study in which 25 male outpatients with chronic obstructive pulmonary disease received pirbuterol aerosol for up to 14 months bronchodilator efficacy was maintained throughout. There were no serious side effects, and laboratory abnormalities were of little clinical relevance. Sinus bradycardia was the most frequently observed ECG change.
D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004983:Ethanolamines / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008875:Middle Aged
D000336:Aerosols; D001993:Bronchodilator Agents; D004983:Ethanolamines; C009118:pirbuterol